Tiagabine

Clinical contraindication: None listed; No clinical contraindication identified.
Best available evidence: Mechanism only
Half-life: 7–9 h; Approximate, in adults. Detail in 01.

Named in state rules?

CONot named

ORNot named

NMPending

Cite asPsilodex: tiagabine · v2026.10.02

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

01 Interaction with psilocybin

Additive CNS depression; can provoke seizures, including in non-epileptics.

Human data with psilocybin: None known: no published human data with psilocybin
Half-life: 7–9 h (2–5 h with enzyme inducers) (FDA label, checked 2026-09-30)

Evidence types on this record

ThMechanism only (theoretical)

02 Pharmacology relevant to psilocybin

2 listed · counted on reports

Sedating or CNS depressant: Slows the central nervous system: drowsiness, slower reactions and impaired coordination, and slowed breathing at high doses. Effects add with other sedating substances. Sources [1]
Lowers seizure threshold or carries seizure risk: Makes a seizure more likely, or has been linked to seizures. Sources [1]

03 State rules

Official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-09-30

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-09-30

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-09-30

04 Conditions to ask about

Screening items in state rules

This medication is usually taken for a condition. State rules screen for some conditions directly, so the medication is a prompt to ask about them. Confirm with the participant; never assume a condition from the medication.

Seizure disorder or bipolar disorder (possible indications)CO 2.5(A)(2)

05 Sources

DESCRIPTION · FDA label (DailyMed)

Report an error in this record →